Abbott Laboratories Corporation

Oslo Universitetssykehus Hf

Life Technologies As

Dynal As

The Norwegian Radium Hospital Research Foundation

Gunnar Kvalheim

Gustav Gaudernack

Sébastien Wälchli

Oystein Fodstad

Harald Holte

Anne-Marie Rasmussen

Else Marit Inderberg Suso

Øystein Fodstad

Otto Sorensen

Else Marit Inderberg

Anne Brunsvig

Eivind Siem

Tanja Aarvak

Erlend Smeland

Walter Gabriell Borelli Piedras

Steinar Funderud

Sèbastien Wälchli

Sebastien Walchli

Else Marit Suso

Anne Marie Rasmussen

June Helen Myklebust

The present invention provides a nucleic acid molecule encoding a specific binding molecule capable of binding an h TERT peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 when the peptide is presented by a Class II Major Histocompatibility Complex (MHC), wherein the specific binding molecule comprises a first polypeptide comprising a variable region of an α-chain and a second polypeptide comprising a variable region of a β-chain of a T-cell receptor (TCR), and wherein: (a) the variable region of an α-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the amino acid sequences set forth in SEQ ID NOs: 2, 3 and 4; and (b) the variable region of a β-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the sequences set forth in SEQ ID NOs: 5, 6 and 7. Recombinant constructs, vectors and host cells comprising such nucleic acid molecules are also provided, as are specific binding molecules encoded by such nucleic acid molecules. The present invention has utility in the treatment of cancer.

Specific binding molecules for hTERT

The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are 'universal'). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.

Universal killer T-cell

Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25&#x2212; T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.

Methods and materials for the generation of regulatory T cells

The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.

Method for detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations

A method and device are provided for separating magnetized particles from biological fluids. Cells such as cancer cells coated with magnetized particles can be separated from uncoated healthy cells. A fluid mixture of cancer cells, healthy cells and magnetizable particles is introduced into a container such as a disposable blood bag which is attached in a cassette on an underlying plane magnetic plane that provides a magnetic field. Incubation is carried out during which the cancer cells become coated with the magnetizable particles. The magnetic field pulls the coated cells down towards the bottom of the bag and anchors them, and uncoated healthy cells are removed from the bag. The separated uncoated healthy cells may be advanced through a final separation unit where any loose magnetizable particles are removed. There is provided means for adjusting vertical distance between the cassette and the magnetic plane and for agitating fluid within the container attached to the cassette. A magnetic screen plate may be placed between the cassette and the magnetic plate to short circuit the magnetic field during incubation. The screen plate is removed to carry out separation.

Magnetic separation of magnetized particles from biological fluids

Growing community of inventors

Oslo, Norway

Gunnar Kvalheim